{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T10:12:16Z","timestamp":1790244736488,"version":"4.1.0"},"reference-count":85,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Facilitators and suppressors of oncogenesis during childhood include many of the proteins and processes critical to development. Neuroblastoma is a childhood cancer that arises from the cells in the neural crest destined to populate the sympathetic nervous system. Among the arbiters and effectors of development in the neural crest are the neurotrophin receptors, Trks A, B, and C and p75NTR; the transcription factors, SIX1 and ATF5; the tyrosine kinase, ALK; and the histone modifiers, EZH2 and the HDACs. During neural development, the relative cellular expression, activation, and translocation of these proteins play important roles in determination of cell fate. We hypothesize that these proteins also play important roles in the chemoresistance of neuroblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This review explores existing evidence to implicate these developmentally relevant proteins and their temporal and spatial inconstancy in the challenge of chemoresistance of neuroblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Literature review methods<\/jats:title>\n                    <jats:p>For examination of the role of developmentally relevant mechanisms in neuroblastoma resistance to chemotherapy, searches of PubMed and ClinicalTrials.gov databases were performed using the following search terms: \u201cneurotrophin receptor\u201d AND \u201cneuroblastoma\u201d; \u201cTrk\u201d AND \u201cneuroblastoma\u201d; \u201cp75NTR\u201d AND \u201cneuroblastoma\u201d; \u201cEZH2 inhibitors\u201d AND \u201cneuroblastoma\u201d; \u201cHDAC inhibitors\u201d AND \u201cneuroblastoma\u201d; \u201cepigenetic\u201d AND \u201cneuroblastoma\u201d AND \u201cresistance\u201d; \u201cALK inhibitors\u201d AND \u201cneuroblastoma\u201d; \u201cPRMT\u201d AND \u201cneuroblastoma\u201d; and \u201cneuroblastoma differentiation\u201d AND \u201ctherapy\u201d. Papers published within the past 10 years were considered for inclusion in discussion of response of neuroblastoma cells and clinical tumors to chemotherapeutic agents and clinical studies closed to recruitment within the past 5 years or continuing to recruit were considered for inclusion in discussion of future therapeutic approaches to clinical neuroblastoma.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Literature evidence synthesis<\/jats:title>\n                    <jats:p>\n                      A total of 317 papers were identified across all initial topics and, of these, 195 were found to be relevant to neuroblastoma therapy. Eleven papers were identified as relevant to 2 or more topics (8 papers, 2 topics; 2 papers, 3 topics; 1 paper, 6 topics), resulting in 175 unique papers identified\n                      <jats:italic>in toto<\/jats:italic>\n                      . The literature supports the notion that developmentally driven heterogeneity and\u00a0changeability of specific protein expression, activation, and translocation in\u00a0neuroblastomas contributes to the refractoriness of neuroblastoma to chemotherapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Therapeutic approaches aimed at inhibition or epigenetic modification of intratumoral neurotrophin receptors, transcription factors, tyrosine kinases, and histone modifiers are currently in clinical trials for neuroblastoma. Future efforts will require both individualization of therapy and emerging technological approaches to the heterogeneity and inconstancy of expression and processing of developmentally relevant proteins in neuroblastoma.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1926773","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:56:44Z","timestamp":1790243804000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Developmentally relevant proteins contribute to chemotherapeutic resistance in neuroblastoma"],"prefix":"10.3389","volume":"16","author":[{"given":"Nina F.","family":"Schor","sequence":"first","affiliation":[{"name":"Departments of Pediatrics and Neurology, University of Rochester School of Medicine & Dentistry","place":["Rochester, NY, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2005.03.007","article-title":"Hypoxia-induced dedifferentiation of tumor cells--a mechanism behind heterogeneity and aggressiveness of solid tumors","volume":"16","author":"Axelson","year":"2005","journal-title":"Semin Cell Dev Biol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1002\/ajmg.10320","article-title":"Cancer genetics","volume":"111","author":"Knudson","year":"2002","journal-title":"Am J Med Genet"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041573","article-title":"Lineage-selective dependencies in pediatric cancers","volume":"15","author":"Ritter","year":"2025","journal-title":"Cold Spring Harb Perspect Med"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3390\/jcm15031101","article-title":"Neuroblastoma in childhood: biological insights, risk stratification, and advances in multimodal therapy","volume":"15","author":"De Bona","year":"2026","journal-title":"J Clin Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1242\/dev.193193","article-title":"Neural crest lineage analysis: from past to future trajectory","volume":"147","author":"Tang","year":"2020","journal-title":"Development"},{"key":"B6","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s13046-022-02281-w","article-title":"Recent advances in the developmental origin of neuroblastoma: an overview","volume":"41","author":"Ponzoni","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms27073238","article-title":"Epigenetic regulation of Trk receptors and neurotrophic signalling in neuroblastoma: Mechanisms, plasticity, and therapeutic opportunities","volume":"27","author":"Siddi","year":"2026","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.16-12-03895.1996","article-title":"Nerve growth factor (NGF)-mediated protection of neural crest cells from antimitotic agent-induced apoptosis: the role of the low-affinity NGF receptor","volume":"16","author":"Cortazzo","year":"1996","journal-title":"J Neurosci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0788-16.2018","article-title":"Neurotrophin responsiveness of sympathetic neurons is regulated by rapid mobilization of the p75 receptor to the cell surface through TrkA activation of Arf6","volume":"38","author":"Hickman","year":"2018","journal-title":"J Neurosci"},{"key":"B10","article-title":"TrkA as a life and death receptor: receptor dose as a mediator of function","volume":"62","author":"Yan","year":"2002","journal-title":"Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1101\/gad.4.5.683","article-title":"Expression of the trk proto-oncogene is restricted to the sensory cranial and spinal ganglia of neural crest origin in mouse development","volume":"4","author":"Martin-Zanca","year":"1990","journal-title":"Genes Dev"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2010.02.024","article-title":"The cholinergic system, nerve growth factor and the cytoskeleton","volume":"221","author":"Niewiadomska","year":"2011","journal-title":"Behav Brain Res"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1006\/dbio.2000.9841","article-title":"Dynamic expression of neurotrophin receptors during sensory neuron genesis and differentiation","volume":"227","author":"Rifkin","year":"2000","journal-title":"Dev Biol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ydbio.2021.08.007","article-title":"The embryonic trunk neural crest microenvironment regulates the plasticity and invasion of human neuroblastoma via TrkB signaling","volume":"480","author":"Kasemeier-Kulesa","year":"2021","journal-title":"Dev Biol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1186\/1471-213X-7-10","article-title":"Embryonic sympathoblasts transiently express TrkB in vivo and proliferate in response to brain-derived neurotrophic factor in vitro","volume":"7","author":"Straub","year":"2007","journal-title":"BMC Dev Biol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aao4006","article-title":"The receptor tyrosine kinase TrkB signals without dimerization at the plasma membrane","volume":"11","author":"Zahavi","year":"2018","journal-title":"Sci Signal"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00244","article-title":"From neural crest development to cancer and vice versa: how p75ntr and (pro)neurotrophins could act on cell migration and invasion","volume":"11","author":"Wislet","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2018.00042","article-title":"A Nogo-like signaling perspective from birth to adulthood and in old age: brain expression patterns of ligands, receptors and modulators","volume":"11","author":"Smedfors","year":"2018","journal-title":"Front Mol Neurosci"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.146","article-title":"Kidins220\/ARMS is expressed in neuroblastoma tumors and stabilizes neurotrophic signaling in a human neuroblastoma cell line","volume":"74","author":"Rogers","year":"2013","journal-title":"Pediatr Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2012.12.027","article-title":"Kidins220\/ARMS depletion is associated with the neural-to Schwann-like transition in a human neuroblastoma cell line model","volume":"319","author":"Rogers","year":"2013","journal-title":"Exp Cell Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1110-x","article-title":"Differential roles of Trk and p75 neurotrophin receptors in tumorigenesis and chemoresistance ex vivo and in vivo","volume":"65","author":"Bassili","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201601050RR","article-title":"Methylation of the phosphatase-transcription activator EYA1 by protein arginine methyltransferase 1: Mechanistic, functional, and structural studies","volume":"31","author":"Li","year":"2017","journal-title":"FASEB J"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.11556","article-title":"Protein arginine methyltransferase 1 is a novel regulator of MYCN in neuroblastoma","volume":"7","author":"Eberhardt","year":"2016","journal-title":"Oncotarget"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25105475","article-title":"Molecular characterization and inhibition of a novel stress-induced mitochondrial protecting role for misfolded TrkAIII in human SH-SY5Y neuroblastoma cells","volume":"25","author":"Cappabianca","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13046-018-0786-3","article-title":"The oncogenic neurotrophin receptor tropomyosin-related kinase variant, TrkAIII","volume":"37","author":"Farina","year":"2018","journal-title":"J Exp Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2026.1739376","article-title":"Advances in multi-omics research on neuroblastoma","volume":"14","author":"Wang","year":"2026","journal-title":"Front Pediatr"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/1096-911X(20010101)36:1<80::AID-MPO1019>3.0.CO;2-N","article-title":"Association among EPHB2, TrkA, and MYCN expression in low-stage neuroblastomas","volume":"36","author":"Tang","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1186\/s40659-018-0167-6","article-title":"Arsenic trioxide induces cell cycle arrest and affects Trk receptor expression in human neuroblastoma SK-N-SH cells","volume":"51","author":"Xiong","year":"2018","journal-title":"Biol Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1083570","article-title":"Study on differentially expressed genes between Stage M and Stage MS neuroblastoma","volume":"12","author":"Wu","year":"2023","journal-title":"Front Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.14312\/2052-4994.2016-3","article-title":"EYA1 expression and subcellular localization in neuroblastoma and its association with prognostic markers","volume":"4","author":"Hansen","year":"2016","journal-title":"J Cancer Res Ther (Manch)"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231810895","article-title":"Doxorubicin-induced trkAIII activation: A selection mechanism for resistant dormant neuroblastoma cells","volume":"23","author":"Cappabianca","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.31083\/j.fbl2907261","article-title":"Genetic identity of neural crest cell differentiation in tissue and organ development","volume":"29","author":"Kyriakoudi","year":"2024","journal-title":"Front Biosci (Landmark Ed)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41580-026-00949-1","article-title":"Neural crest gene regulatory networks as drivers of development, diversification and disease","volume":"27","author":"Stundl","year":"2026","journal-title":"Nat Rev Mol Cell Biol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2011.08.001","article-title":"The MYCN oncogene and differentiation in neuroblastoma","volume":"21","author":"Westermark","year":"2011","journal-title":"Semin Cancer Biol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16030544","article-title":"Retinoid therapy for neuroblastoma: Historical overview, regulatory challenges, and prospects","volume":"16","author":"Makimoto","year":"2024","journal-title":"Cancers"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/7568287","article-title":"Cell line-dependent variability of coordinate expression of p75NTR and CRABP1 and modulation of effects of fenretinide on neuroblastoma cells","volume":"2016","author":"Yang","year":"2016","journal-title":"Oxid Med Cell Longev"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.17294","article-title":"Immunoliposomes for neuroblastoma: Review of the past experience and design of a novel nanoparticle","volume":"44","author":"Panosyan","year":"2024","journal-title":"Anticancer Res"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.597","article-title":"Transcriptomic analysis reveals the role of SIX1 in mouse cranial neural crest patterning and bone development","volume":"252","author":"Baxi","year":"2023","journal-title":"Dev Dyn"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/dvdy.109","article-title":"Cis-control of Six1 expression in neural crest cells during craniofacial development","volume":"248","author":"Wu","year":"2019","journal-title":"Dev Dyn"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1242\/dev.00536","article-title":"Six1 is required for the early organogenesis of mammalian kidney","volume":"130","author":"Xu","year":"2003","journal-title":"Development"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.21102","article-title":"The transcription factor ATF5: role in cellular differentiation, stress responses, and cancer","volume":"8","author":"Sears","year":"2017","journal-title":"Oncotarget"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18162700","article-title":"The TBX18\/SIX1 Transcriptional circuit maintains stemness and EMT states to promote radioresistance in ESCC","volume":"18","author":"Gu","year":"2026","journal-title":"Cancers (Basel)"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2026.218770","article-title":"The GCN5L2-SIX1 complex drives glycolysis to promote progression of triple-negative breast cancer","volume":"659","author":"Liao","year":"2026","journal-title":"Cancer Lett"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2026.117007","article-title":"Glycolytic reprogramming and the EMT drive cervical cancer progression via the NQO1\/HIF1\u03b1-SIX1 axis","volume":"29","author":"Zhu","year":"2026","journal-title":"iScience"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.70359","article-title":"GRP78 Drives NSCLC stemness and EMT via a SIX1\/\u03b2-Catenin signaling axis","volume":"87","author":"Tong","year":"2026","journal-title":"Drug Dev Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-23-0154","article-title":"Activating Transcription Factor 5 promotes neuroblastoma metastasis by inducing anoikis resistance","volume":"3","author":"Banerjee","year":"2023","journal-title":"Cancer Res Commun"},{"key":"B47","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41389-020-0237-9","article-title":"PRMT1 promotes neuroblastoma cell survival through ATF5","volume":"9","author":"Hua","year":"2020","journal-title":"Oncogenesis"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02276-0","article-title":"Phase 1 study of GSK3368715, a type I PRMT inhibitor, in patients with advanced solid tumors","volume":"129","author":"El-Khoueiry","year":"2023","journal-title":"Br J Cancer"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1719137115","article-title":"ALKALs are in vivo ligands for ALK family receptor tyrosine kinases in the neural crest and derived cells","volume":"115","author":"Fadeev","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1242\/dev.164046","article-title":"Leukocyte receptor tyrosine kinase interacts with secreted midkine to promote survival of migrating neural crest cells","volume":"145","author":"Vieceli","year":"2018","journal-title":"Development"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.gep.2021.119183","article-title":"Anaplastic lymphoma kinase (alk), a neuroblastoma associated gene, is expressed in neural crest domains during embryonic development of Xenopus","volume":"40","author":"Moreno","year":"2021","journal-title":"Gene Expr Patterns"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmb.2021.167283","article-title":"Mapping the phospho-dependent ALK interactome to identify novel components in ALK signaling","volume":"433","author":"Aboualizadeh","year":"2021","journal-title":"J Mol Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00579","article-title":"Alectinib, an anaplastic lymphoma kinase inhibitor, abolishes ALK activity and growth in ALK-positive neuroblastoma cells","volume":"9","author":"Alam","year":"2019","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.23093","article-title":"Loss of ALK hotspot mutations in relapsed neuroblastoma","volume":"61","author":"Allinson","year":"2022","journal-title":"Genes Chromosomes Cancer"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00086","article-title":"Frequency and prognostic impact of ALK amplifications and mutations in the European Neuroblastoma Study Group (SIOPEN) high-risk neuroblastoma trial (HR-NBL1)","volume":"39","author":"Bellini","year":"2021","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"16863","DOI":"10.1038\/s41598-017-17319-9","article-title":"High expression of \u03b2-catenin contributes to the crizotinib resistant phenotype in the stem-like cell population in neuroblastoma","volume":"7","author":"Alshareef","year":"2017","journal-title":"Sci Rep"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics13091427","article-title":"Therapeutic targeting of the anaplastic lymphoma kinase (ALK) in neuroblastoma-a comprehensive update","volume":"13","author":"Brenner","year":"2021","journal-title":"Pharmaceutics"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1097\/MS9.0000000000003697","article-title":"Integration of ALK gene mutations and targeted therapies in pediatric high-risk neuroblastoma: advancements in precision oncology","volume":"87","author":"Bheemavarapu","year":"2025","journal-title":"Ann Med Surg (Lond)"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02297-5","article-title":"Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results","volume":"29","author":"Goldsmith","year":"2023","journal-title":"Nat Med"},{"key":"B60","doi-asserted-by":"publisher","first-page":"19353","DOI":"10.1038\/s41598-019-55060-7","article-title":"Repotrectinib (TPX-0005), effectively reduces growth of ALK driven neuroblastoma cells","volume":"9","author":"Cervantes-Madrid","year":"2019","journal-title":"Sci Rep"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-24-0684","article-title":"Kinome reprogramming of G2\/M kinases and repression of MYCN contribute to superior efficacy of lorlatinib in ALK-driven neuroblastoma","volume":"24","author":"Matkar","year":"2025","journal-title":"Mol Cancer Ther"},{"key":"B62","unstructured":"NCT02650401, NCT03107988, NCT00939770, NCT03126916, and NCT03155620"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1732","article-title":"Impact of ALK inhibitors to potentiate ALK.CAR-T therapy in neuroblastoma","volume":"14","author":"Bergaggio","year":"2024","journal-title":"Clin Transl Med"},{"key":"B64","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s12943-022-01583-z","article-title":"Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells","volume":"21","author":"Berlak","year":"2022","journal-title":"Mol Cancer"},{"key":"B65","first-page":"2026.02.19.706849","article-title":"Daraxonrasib (RMC-6236) is an effective targeted therapy for RAS -mutant neuroblastoma","volume-title":"Biorxiv [Preprint]","author":"Hill","year":"2026"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-018-0397-7","article-title":"Bruton\u2019s tyrosine kinase potentiates ALK signaling and serves as a potential therapeutic target of neuroblastoma","volume":"37","author":"Li","year":"2018","journal-title":"Oncogene"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1621","article-title":"Mesenchymal-type neuroblastoma cells escape ALK inhibitors","volume":"82","author":"Westerhout","year":"2022","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aee7295","article-title":"The impactful role of the HDACs in the regulation of gene expression and as targets for disease therapy","volume":"12","author":"Van Bree","year":"2026","journal-title":"Sci Adv"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abf7472","article-title":"Ciliary protein Kif7 regulates Gli and Ezh2 for initiating the neuronal differentiation of enteric neural crest cells during development","volume":"7","author":"Lai","year":"2021","journal-title":"Sci Adv"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0203391","article-title":"Ablation of Ezh2 in neural crest cells leads to aberrant enteric nervous system development in mice","volume":"13","author":"Kim","year":"2018","journal-title":"PloS One"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113032","article-title":"Reversing the HDAC-inhibitor mediated metabolic escape in MYCN-amplified neuroblastoma","volume":"150","author":"Bishayee","year":"2022","journal-title":"BioMed Pharmacother"},{"key":"B72","article-title":"Novel combination of imipridones and histone deacetylase inhibitors demonstrate cytotoxic effect through integrated stress response in pediatric solid tumors","volume":"13","author":"Chang","year":"2023","journal-title":"Am J Cancer Res"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1172\/JCI90793","article-title":"CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2","volume":"128","author":"Chen","year":"2018","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0246244","article-title":"EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth","volume":"16","author":"Bownes","year":"2021","journal-title":"PloS One"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.31619","article-title":"Phase I study of vorinostat and temsirolimus in newly diagnosed or progressive diffuse intrinsic pontine glioma","volume":"72","author":"Stitzlein","year":"2025","journal-title":"Pediatr Blood Cancer"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-01712-w","article-title":"A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma","volume":"40","author":"Cheung","year":"2021","journal-title":"Oncogene"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2025.130495","article-title":"Design, synthesis and biological evaluation of ALK\/HDAC dual-targeting agents","volume":"133","author":"Kong","year":"2026","journal-title":"Bioorg Med Chem Lett"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2024.106921","article-title":"Discovery of organosulfur-based selective HDAC8 inhibitors with anti-neuroblastoma activity","volume":"203","author":"Cho","year":"2024","journal-title":"Eur J Pharm Sci"},{"key":"B79","unstructured":"NCT03155620: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, non-Hodgkin Lymphomas, or Histiocytic Disorders (the Pediatric MATCH Screening Trial)"},{"key":"B80","unstructured":"Tazemetostat withdrawn from all trials and markets due to safety concerns\n          \n          \n            \n              Britt\n              P\n            \n          \n          Targeted Oncol\n          \n          2026"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.soc.2026.04.012","article-title":"Neuroblastoma","volume":"35","author":"Kotagal","year":"2026","journal-title":"Surg Oncol Clin N Am"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.97195","article-title":"A small molecule selectively targets N-Myc to suppress neuroblastoma cancer progression","volume":"21","author":"Miao","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B83","unstructured":"NCT00020579: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01270-8","article-title":"Neuroblastoma heterogeneity, plasticity, and emerging therapies","volume":"24","author":"Lundberg","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.5c00858","article-title":"Mapping the interactions among class IIa histone deacetylases and myocyte enhancer factor 2s","volume":"65","author":"Gautam","year":"2025","journal-title":"J Chem Inf Model"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1926773\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:56:47Z","timestamp":1790243807000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1926773\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":85,"alternative-id":["10.3389\/fonc.2026.1926773"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1926773","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1926773"}}